STOCK TITAN

AIM ImmunoTech (AIM) Stock News

AIM NYSE

AIM ImmunoTech Inc. develops immuno-pharma therapeutics led by Ampligen (rintatolimod), a dsRNA and selective TLR3 agonist immuno-modulator under development for late-stage pancreatic cancer and other cancer, viral disease and immune-disorder indications. Company news commonly covers clinical disclosures for Ampligen, including pancreatic cancer studies with checkpoint inhibitors, intellectual-property approvals, and regulatory designations.

Updates also address financing and capital-structure actions, such as rights offerings, preferred stock and warrant terms, at-the-market equity arrangements, shareholder voting matters, governance disclosures, operating results, and public-company reporting matters including audit and going-concern disclosures.

Rhea-AI Summary

AIM ImmunoTech (AIM) adjourned its 2026 annual shareholder meeting for lack of a quorum and will reconvene it on December 8, 2026.

When the November 17 meeting adjourned, submitted proxies represented approximately 32.5% of outstanding shares entitled to vote. The quorum threshold was 33 and 1/3% of outstanding common shares entitled to vote, present or represented by proxy. The meeting will resume virtually at 11:00 a.m. Eastern Time. The proposals are unchanged, and the voting record date remains the close of business on September 28, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.75%
Tags
none
-
Rhea-AI Summary

AIM ImmunoTech (NYSE American: AIM) will participate in the Webull Corporate Connect Webinar Series on November 12, 2026. Chief Executive Officer Thomas K. Equels will present during the virtual event, with the live webcast scheduled for 2:40 PM ET.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.10%
Tags
none
-
Rhea-AI Summary

AIM ImmunoTech (AIM) outlined a proposed strategy to investigate Ampligen alongside daraxonrasib or as maintenance after daraxonrasib in pancreatic cancer. The strategy is not an established clinical trial protocol.

Previously reported exploratory data from a nonrandomized program showed median overall survival of 19.7 months in Ampligen-treated patients versus 12.5 months in historical controls. Separately, DURIPANC is evaluating Ampligen with durvalumab in metastatic pancreatic cancer after stable disease following FOLFIRINOX chemotherapy. AIM expects Phase 2 topline results on clinical benefit at 24 weeks in Q1 2027, followed by additional analyses in Q3 2027. Interim findings included three Grade 3 immune-related adverse events.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.53%
Tags
none
Rhea-AI Summary

AIM ImmunoTech (AIM) highlighted a BioTuesdays feature examining Ampligen’s potential as maintenance therapy after first-line chemotherapy for metastatic pancreatic cancer.

Final Ampligen dosing is complete in DURIPANC, which evaluates Ampligen with AstraZeneca’s Imfinzi; primary and secondary endpoint reporting remains pending. AIM is working toward further clinical development. In an exploratory Named Patient Program analysis, 39 patients with a neutrophil-to-lymphocyte ratio, an immune-cell measure, below 4.5 had median overall survival of 34.8 months from the start of FOLFIRINOX chemotherapy. The program was not a controlled clinical trial, and historical comparisons do not establish efficacy. The feature also discusses patents, pancreatic cancer orphan drug designations and potential financing or pharmaceutical partnerships to support a pivotal Phase 3 study.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.16%
Tags
none
-
Rhea-AI Summary

AIM ImmunoTech (AIM) highlighted recent media coverage examining its investigational drug Ampligen’s potential antiviral and post-viral therapeutic applications.

Healthcare Business Today featured CEO Tom Equels discussing preparedness for viral outbreaks, while MediTech Today examined AIM’s Long COVID patent protection. AIM describes Ampligen’s possible applications as including emerging viral threats such as Ebola Virus Disease and post-viral conditions. Ampligen is also being studied in the company’s oncology clinical program, which focuses on pancreatic cancer.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.56%
Tags
none
-
Rhea-AI Summary

AIM ImmunoTech (AIM) highlighted Ampligen’s pancreatic cancer development strategy as the Phase 2 DURIPANC trial completed final Ampligen dosing.

DURIPANC evaluates Ampligen with AstraZeneca’s Imfinzi in metastatic pancreatic cancer. AIM expects topline results in the first quarter of 2027. Interim reports suggest activation of both innate and adaptive immune responses; the combination was reported as well-tolerated, with patients reporting high quality of life throughout treatment.

AIM also completed a Netherlands-approved Named Patient Program involving 57 patients with radiologically stable pancreatic cancer after FOLFIRINOX, who received Ampligen as maintenance treatment. The company described survival, safety and quality-of-life findings as encouraging.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.26%
Tags
Rhea-AI Summary

AIM ImmunoTech (AIM) released a CEO Corner video discussing Ampligen’s potential role alongside or after other pancreatic cancer therapies.

An exploratory analysis of 39 patients with a neutrophil-to-lymphocyte ratio (NLR), a blood-cell ratio, below 4.5 found median overall survival of 34.8 months from the start of FOLFIRINOX chemotherapy. These patients received Ampligen maintenance after radiologically stable disease. Differences in patient selection, disease stage, treatment setting and survival measurement prevent direct comparisons with separate therapy trials.

The ongoing Phase 2 DURIPANC study evaluates Ampligen with AstraZeneca’s durvalumab in metastatic pancreatic cancer. Its primary endpoint is clinical benefit rate at 24 weeks after combination therapy starts. AIM expects topline results in Q1 2027 and overall survival analysis to begin in Q3 2027.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.86%
Tags
management
-
Rhea-AI Summary

AIM ImmunoTech (AIM) released a CEO letter outlining how its investigational drug Ampligen could fit into pancreatic cancer treatment following the FDA approval of daraxonrasib for metastatic disease.

Ampligen is described as a TLR3 agonist designed to activate innate immunity and reshape the tumor microenvironment, in contrast to daraxonrasib, which directly inhibits RAS. In a Dutch government‑approved Named Patient Program, Ampligen monotherapy in patients with a blood neutrophil‑to‑lymphocyte ratio below 4.5 was associated with a median overall survival of 34.8 months, versus 12.5 months in well‑matched historical controls, an observed difference of 22.3 months. AIM sees potential for Ampligen both as monotherapy and in combinations such as with checkpoint inhibitors.

The ongoing Phase 2 DURIPANC trial is testing Ampligen plus durvalumab in patients with pancreatic cancer stable after FOLFIRINOX, with topline data expected in Q1 2027 and overall‑survival analysis in Q3 2027. Ampligen already has FDA and EMA orphan designations for pancreatic cancer, and AIM plans to use upcoming data to define a potential pivotal Phase 3 trial.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.91%
Tags
none
-
Rhea-AI Summary

On September 9, 2026, AIM ImmunoTech (AIM) released a new CEO Corner video outlining its scientific strategy and clinical progress with Ampligen (rintatolimod) in pancreatic cancer.

The video highlights Ampligen, an investigational TLR3 agonist designed to activate innate immunity and reshape the tumor microenvironment to potentially enhance responses to PD-1 and PD-L1 checkpoint inhibitors. The company focuses on the ongoing Phase 2 DURIPANC study, which evaluates Ampligen combined with AstraZeneca’s durvalumab as maintenance therapy after standard-of-care treatment. AIM also discusses biomarker research, collaborations, IP expansion, regulatory engagement, and upcoming DURIPANC milestones, including primary endpoint analyses and overall survival follow-up.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.52%
Tags
management
Rhea-AI Summary

AIM ImmunoTech (AIM) announced expanded patent protection for its drug Ampligen in the treatment of Long COVID across major European markets and the United Kingdom, with coverage expected to run through June 2041.

The protection consists of three forms of patents in Europe and the UK that became final after a nine‑month opposition period under the European Patent Convention closed on August 25, 2026, with no opposition filed. This follows a newly issued U.S. patent covering Ampligen in combination with pembrolizumab for cancer treatment, broadening Ampligen’s global intellectual property estate across multiple therapeutic areas.

The granted claims cover therapeutic double stranded RNA for treating Long COVID, including specific dosing regimens and intranasal, intravenous and inhalation administration, with Ampligen included in this scope. The company reports that Ampligen has undergone extensive clinical and preclinical testing in more than 1,200 patients receiving over 100,000 doses, with no drug-related deaths and favorable safety profiles across several routes of administration.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.59%
Tags
covid-19

FAQ

What is the current stock price of AIM ImmunoTech (AIM)?

AIM ImmunoTech (AIM) last closed at $0.1146.

What is the market cap of AIM ImmunoTech (AIM)?

The market cap of AIM ImmunoTech (AIM) is approximately $4.6M.